Synergy Pharmaceuticals Inc.filed for FDA approval in January this year for the once-daily tablet plecanatide, a uroguanylin analog, as a treatment for chronic idiopathic constipation (CIC). The NDA has been accepted for FDA review with a PDUFA target action date of January 29, 2017.
The plecanatide NDA was supported by two double-blind placebo-controlled Phase III trials (Study-00 and Study-03) and one open-label long term...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)